

## Ghana Support for Yellow Fever Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Ghana			
<b>2. Grant number:</b> 1719-GHA-06b-X			
<b>3. Date of Decision Letter:</b> 19 March 2019			
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014			
<b>5. Programme title:</b> NVS, Yellow Fever Routine			
<b>6. Vaccine type:</b> Yellow Fever			
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED			
<b>8. Programme duration<sup>1</sup>:</b> 2001 -2019			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2001-2018	2019	Total <sup>2</sup>
Programme Budget (US\$)	US\$12,060,007 <sup>3</sup>	US\$1,519,000	US\$13,579,007
<b>10. Vaccine introduction grant (in US\$):</b>			
Not applicable			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable): <sup>4</sup>																
Type of supplies to be purchased with Gavi funds in each year	2001-2018	2019														
Number of Yellow Fever vaccines doses		1,243,500														
Annual Amounts (US\$)	US\$12,060,007 <sup>5</sup>	US\$1,519,000														
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.																
<b>13. Self-procurement:</b> Not applicable																
<p><b>14. Co-financing obligations: Reference code:</b> 1719-GHA-06b-X-C          According to the co-financing policy, the Country falls within the group Preparatory transition.          The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2019</td> </tr> <tr> <td>Number of vaccine doses</td> <td>525,100</td> </tr> <tr> <td>Number of AD syringes</td> <td>458,600</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>57,800</td> </tr> <tr> <td>Number of safety boxes</td> <td>5,700</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$614,360</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$665,500</td> </tr> </table>			Type of supplies to be purchased with Country funds in each year	2019	Number of vaccine doses	525,100	Number of AD syringes	458,600	Number of re-constitution syringes	57,800	Number of safety boxes	5,700	Value of vaccine doses (US\$)	US\$614,360	Total co-financing payments (US\$) (including freight)	US\$665,500
Type of supplies to be purchased with Country funds in each year	2019															
Number of vaccine doses	525,100															
Number of AD syringes	458,600															
Number of re-constitution syringes	57,800															
Number of safety boxes	5,700															
Value of vaccine doses (US\$)	US\$614,360															
Total co-financing payments (US\$) (including freight)	US\$665,500															
<b>15. Operational support for campaigns:</b> Not applicable																
<b>16. Additional reporting requirements:</b>																
Reports and information	Due dates															
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:																
• vaccine stock levels including buffer stock, by end of March;	31 March 2019															
• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing	15 May 2019															

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</p>	
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
<p><b>17. Financial clarifications:</b> Not applicable</p>	
<p><b>18. Other conditions:</b> There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.</p>	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 March 2019